NVCR - NovoCure Limited
NASDAQ
->
Healthcare
->
Medical Instruments & Supplies
Saint Helier,
Jersey
Type: Equity
NVCR price evolution
NVCR
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $13.77 | $168.44 | $457.36 | $242.56 |
| Short term investments | $786.39 | $416.38 | $669.79 | |
| Net receivables | $92.5 | $97.56 | $86.57 | $83.9 |
| Inventory | $39.1 | $40.44 | $42.39 | $38.15 |
| Total current assets | $1095.27 | $1092.84 | $1002.71 | $1034.41 |
| Long term investments | ||||
| Property, plant & equipment | $114.49 | $107.27 | $103.82 | $97.7 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $119.33 | $118.72 | $111.72 | |
| Total investments | $786.39 | $416.38 | $669.79 | |
| Total assets | $1221.99 | $1212.17 | $1121.43 | $1146.13 |
| Current liabilities | ||||
| Accounts payable | $91.32 | $90.17 | $84.32 | $94.39 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $735 | $169.18 | $160.23 | $179.12 |
| Long term debt | $97.15 | $675.2 | $595.26 | $596.24 |
| Total noncurrent liabilities | $681.24 | $601.84 | $604.52 | |
| Total debt | $675.2 | $595.26 | $596.24 | |
| Total liabilities | $861.21 | $850.42 | $762.07 | $783.63 |
| Shareholders' equity | ||||
| Retained earnings | -$1088.21 | -$1057.64 | -$1024.26 | -$985.5 |
| Other shareholder equity | -$5.38 | -$3.52 | -$4.15 | -$5.47 |
| Total shareholder equity | $361.75 | $359.36 | $362.5 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $242.56 | $9.7 | $209.61 | $246.17 |
| Short term investments | $669.79 | $854.1 | $728.9 | $607.9 |
| Net receivables | $83.9 | $106.03 | $110.59 | $117.94 |
| Inventory | $38.15 | $29.38 | $24.43 | $27.42 |
| Total current assets | $1034.41 | $1111.53 | $1073.53 | $999.44 |
| Long term investments | ||||
| Property, plant & equipment | $97.7 | $68.96 | $53.88 | $41.63 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $111.72 | $80.12 | $65.97 | $52.54 |
| Total investments | $669.79 | $854.1 | $728.9 | $607.9 |
| Total assets | $1146.13 | $1191.65 | $1139.49 | $1051.98 |
| Current liabilities | ||||
| Accounts payable | $94.39 | $85.2 | $72.6 | $113.61 |
| Deferred revenue | $2.88 | $6.48 | $12.14 | |
| Short long term debt | ||||
| Total current liabilities | $179.12 | $158.78 | $142.6 | $113.61 |
| Long term debt | $596.24 | $565.51 | $575.21 | $444.2 |
| Total noncurrent liabilities | $604.52 | $591.7 | $586.4 | $461.85 |
| Total debt | $596.24 | $584.27 | $575.21 | $444.2 |
| Total liabilities | $783.63 | $750.48 | $729 | $575.46 |
| Shareholders' equity | ||||
| Retained earnings | -$985.5 | -$778.46 | -$685.93 | -$631.08 |
| Other shareholder equity | -$5.47 | -$2.43 | -$3.17 | -$3.83 |
| Total shareholder equity | $362.5 | $441.17 | $410.49 | $476.53 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $155.09 | $150.36 | $138.5 | $133.78 |
| Cost of revenue | $34.65 | $33.69 | $32.56 | |
| Gross Profit | $119.72 | $115.7 | $104.81 | $101.23 |
| Operating activities | ||||
| Research & development | $54.95 | $51.6 | $54.31 | |
| Selling, general & administrative | $94.33 | $94.74 | $98.64 | |
| Total operating expenses | $151.81 | $149.28 | $146.33 | $152.94 |
| Operating income | -$33.58 | -$41.52 | -$51.72 | |
| Income from continuing operations | ||||
| EBIT | -$33.58 | -$41.52 | -$51.72 | |
| Income tax expense | $8.98 | $10.65 | $7.12 | $8.54 |
| Interest expense | $10.51 | -$10.85 | -$9.88 | -$13.18 |
| Net income | ||||
| Net income | -$30.57 | -$33.38 | -$38.76 | -$47.08 |
| Income (for common shares) | -$33.38 | -$38.76 | -$47.08 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $509.34 | $537.84 | $535.03 | $494.37 |
| Cost of revenue | $128.28 | $114.87 | $114.88 | $106.5 |
| Gross Profit | $381.06 | $422.97 | $420.15 | $387.87 |
| Operating activities | ||||
| Research & development | $223.06 | $206.09 | $201.3 | $132.01 |
| Selling, general & administrative | $390.87 | $306.41 | $263.18 | $225.45 |
| Total operating expenses | $613.93 | $512.5 | $464.49 | $357.46 |
| Operating income | -$232.87 | -$89.52 | -$44.33 | $30.4 |
| Income from continuing operations | ||||
| EBIT | -$232.87 | -$89.52 | -$44.33 | $30.4 |
| Income tax expense | $15.3 | $10.69 | $6.28 | -$1.71 |
| Interest expense | -$41.13 | -$7.68 | $7.74 | $12.3 |
| Net income | ||||
| Net income | -$207.04 | -$92.53 | -$58.35 | $19.81 |
| Income (for common shares) | -$207.04 | -$92.53 | -$58.35 | $19.81 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$33.38 | -$38.76 | -$47.08 | |
| Operating activities | ||||
| Depreciation | $2.86 | $2.81 | $2.72 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $31.83 | $34.08 | $17.44 | |
| Total cash flows from operations | -$1.72 | -$31.57 | -$14.56 | |
| Investing activities | ||||
| Capital expenditures | -$11.45 | -$11.78 | -$6.82 | |
| Investments | -$362.99 | $258 | $105.32 | |
| Total cash flows from investing | -$118.03 | -$374.44 | $246.22 | $98.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.19 | $1.53 | ||
| Net borrowings | $84.01 | |||
| Total cash flows from financing | $87.63 | $87.32 | $0.21 | $1.91 |
| Effect of exchange rate | -$0.05 | -$0.08 | -$0.06 | $0.2 |
| Change in cash and equivalents | -$53.37 | -$288.92 | $214.8 | $86.05 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$207.04 | -$92.53 | -$58.35 | $19.81 |
| Operating activities | ||||
| Depreciation | $10.97 | $10.62 | $10.25 | $9.15 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $115.61 | $106.95 | $94.9 | $75.72 |
| Total cash flows from operations | -$73.34 | $30.79 | $82.76 | $99.15 |
| Investing activities | ||||
| Capital expenditures | -$27.09 | -$21.36 | -$24.17 | -$14.97 |
| Investments | $211.24 | -$118.6 | -$120.66 | -$457.88 |
| Total cash flows from investing | $184.15 | -$139.96 | -$144.83 | -$472.85 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $4.42 | $5.22 | $4.55 | $3.37 |
| Net borrowings | -$0.01 | -$0.03 | -$0.03 | $408.41 |
| Total cash flows from financing | $15.79 | $15.49 | $25.7 | $440.21 |
| Effect of exchange rate | $0.13 | -$0.1 | -$0.19 | $0.25 |
| Change in cash and equivalents | $126.73 | -$93.78 | -$36.56 | $66.76 |
News
Fundamentals
| Market cap | $1.45B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 108.10M |
| Revenue | $577.74M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$149.78M |
| Revenue Q/Q | 21.81% |
| Revenue Y/Y | 14.63% |
| P/E ratio | -9.65 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 2.50 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.13 |
| EPS | -$1.39 |
|---|---|
| ROA | -12.74% |
| ROE | N/A |
| Debt/Equity | 2.16 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.49 |
| Quick ratio | 1.44 |